All In Biotech

Drug Trial Radar · NCT07633470

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

May 20, 2026

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Alpha Cognition, IncIndustry
Sponsor type
Industry
First posted
Jun 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

  • Zunveyl®Drug

    Zunveyl® delayed release oral tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Week 1 up to Week 12
  2. Percentage of Participants who Discontinued due to AEsTime frame: From Week 1 up to Week 12
  3. Number of Participants with Treatment Interruptions or Dose ReductionsTime frame: From Week 1 up to Week 12
  4. Global Tolerability ScoreTime frame: At Weeks 1, 2, 4, 6, 8 12, and 17

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Progeny Psychiatric Clinic - Irvine

    Irvine, California · Recruiting

  • ATP Clinical Research, Inc - Orange

    Orange, California · Recruiting

  • First Choice Neurology - Aventura Neurologic Associates

    Aventura, Florida · Recruiting

  • Galiz Research

    Hialeah, Florida · Recruiting

  • Clincloud, LLC - Viera Office

    Melbourne, Florida · Recruiting

  • Allied Biomedical Research Institute (ABRI), Inc

    Miami, Florida · Recruiting

  • CCM Clinical Research Group, LLC

    Miami, Florida · Recruiting

  • Progressive Medical Research

    Port Orange, Florida · Recruiting

  • Accel Research - NeuroStudies

    Decatur, Georgia · Recruiting

  • Flourish Research Andersonville

    Chicago, Illinois · Recruiting

  • Essential Concepts Research Solutions (ECRS)

    Palos Hills, Illinois · Recruiting

  • NexGen Research

    Fort Wayne, Indiana · Recruiting

  • Josephson Wallack Munshower Neurology P.C.

    Indianapolis, Indiana · Recruiting

  • ActivMed Practices & Research, LLC

    Methuen, Massachusetts · Recruiting

  • Adams Clinical - Watertown

    Watertown, Massachusetts · Recruiting

  • Quest Research Institute

    Farmington Hills, Michigan · Recruiting

  • Tekton Research Saint Louis Psychiatry

    St Louis, Missouri · Recruiting

  • Psympatica, LLC

    St Louis, Missouri · Recruiting

  • Advanced Memory Research Institute of New Jersey

    Toms River, New Jersey · Recruiting

  • Alzheimer's Disease Research Center

    Albany, New York · Recruiting

  • Valley Medical Research - Centerville

    Centerville, Ohio · Recruiting

  • Neurology Diagnostics Inc

    Dayton, Ohio · Recruiting

  • Circle Clinical Research

    Sioux Falls, South Dakota · Recruiting

  • Neurology Clinic, P.C.

    Cordova, Tennessee · Recruiting

  • Mt. Olympus Medical Research, Llc - Katy

    Katy, Texas · Recruiting

  • Boeson Research

    Provo, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.